MX2023009630A - Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente. - Google Patents
Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente.Info
- Publication number
- MX2023009630A MX2023009630A MX2023009630A MX2023009630A MX2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A MX 2023009630 A MX2023009630 A MX 2023009630A
- Authority
- MX
- Mexico
- Prior art keywords
- aqueous solution
- stability
- increase
- compositions
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2102258.7A GB202102258D0 (en) | 2021-02-17 | 2021-02-17 | Novel composition |
| PCT/US2022/016864 WO2022178175A1 (en) | 2021-02-17 | 2022-02-17 | Aqueous solution compositions for increasing stability of engineered dimeric proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023009630A true MX2023009630A (es) | 2023-11-06 |
Family
ID=75338972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009630A MX2023009630A (es) | 2021-02-17 | 2022-02-17 | Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente. |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220265788A1 (https=) |
| EP (1) | EP4294372A1 (https=) |
| JP (1) | JP2024506718A (https=) |
| KR (1) | KR20230147140A (https=) |
| CN (1) | CN117279624A (https=) |
| AU (1) | AU2022224607A1 (https=) |
| BR (1) | BR112023016442A2 (https=) |
| CA (1) | CA3208704A1 (https=) |
| GB (1) | GB202102258D0 (https=) |
| IL (1) | IL305142A (https=) |
| MX (1) | MX2023009630A (https=) |
| WO (1) | WO2022178175A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023225513A1 (en) * | 2022-05-16 | 2023-11-23 | Inhibrx, Inc. | Effective dosage of recombinant serpin-fc fusion protein for use in a method of treating aat deficiency in a subject |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1478394T1 (sl) * | 2002-02-27 | 2008-12-31 | Immunex Corp | STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM |
| KR101235507B1 (ko) * | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
| ATE530165T1 (de) * | 2003-11-14 | 2011-11-15 | Baxter Int | Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen |
| PL1789434T3 (pl) * | 2004-08-31 | 2014-07-31 | Novo Nordisk As | Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek |
| BRPI0611901A2 (pt) * | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
| AU2006318583A1 (en) * | 2005-11-22 | 2007-05-31 | Wyeth | Immunoglobulin fusion protein formulations |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| EP2598167B1 (en) * | 2010-07-30 | 2015-04-01 | Arecor Limited | Stabilized aqueous antibody compositions |
| EA201391489A1 (ru) * | 2011-04-07 | 2014-02-28 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Композиции со сниженной вязкостью |
| KR102231139B1 (ko) | 2011-06-28 | 2021-03-24 | 인히브릭스, 인크. | 세르핀 융합 폴리펩타이드 및 이의 이용 방법 |
| CA2896951A1 (en) * | 2012-01-10 | 2013-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
| US9527890B2 (en) * | 2013-06-18 | 2016-12-27 | The Brigham And Womens's Hospital, Inc. | FC receptor (FcRn) binding peptides and uses thereof |
| RU2727639C2 (ru) * | 2014-01-15 | 2020-07-22 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а |
| EP3155117A4 (en) * | 2014-06-11 | 2017-11-22 | Beth Israel Deaconess Medical Center, Inc. | Alpha1-antitrypsin compositions and methods of treating autoimmune diseases |
| NZ769391A (en) * | 2014-10-27 | 2024-12-20 | Sanofi Aatd Inc | Serpin fusion polypeptides and methods of use thereof |
| GB201703063D0 (en) * | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
| GB201721846D0 (en) * | 2017-12-22 | 2018-02-07 | Arecor Ltd | Novel composition |
-
2021
- 2021-02-17 GB GBGB2102258.7A patent/GB202102258D0/en not_active Ceased
-
2022
- 2022-02-17 AU AU2022224607A patent/AU2022224607A1/en active Pending
- 2022-02-17 KR KR1020237031527A patent/KR20230147140A/ko active Pending
- 2022-02-17 JP JP2023549616A patent/JP2024506718A/ja active Pending
- 2022-02-17 CN CN202280028860.9A patent/CN117279624A/zh active Pending
- 2022-02-17 BR BR112023016442A patent/BR112023016442A2/pt unknown
- 2022-02-17 US US17/674,713 patent/US20220265788A1/en not_active Abandoned
- 2022-02-17 CA CA3208704A patent/CA3208704A1/en active Pending
- 2022-02-17 IL IL305142A patent/IL305142A/en unknown
- 2022-02-17 MX MX2023009630A patent/MX2023009630A/es unknown
- 2022-02-17 EP EP22709101.4A patent/EP4294372A1/en active Pending
- 2022-02-17 WO PCT/US2022/016864 patent/WO2022178175A1/en not_active Ceased
-
2024
- 2024-09-30 US US18/902,711 patent/US20250177501A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220265788A1 (en) | 2022-08-25 |
| IL305142A (en) | 2023-10-01 |
| CN117279624A (zh) | 2023-12-22 |
| CA3208704A1 (en) | 2022-08-25 |
| JP2024506718A (ja) | 2024-02-14 |
| KR20230147140A (ko) | 2023-10-20 |
| EP4294372A1 (en) | 2023-12-27 |
| BR112023016442A2 (pt) | 2023-10-10 |
| GB202102258D0 (en) | 2021-03-31 |
| US20250177501A1 (en) | 2025-06-05 |
| AU2022224607A1 (en) | 2023-08-31 |
| WO2022178175A1 (en) | 2022-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Söderhäll et al. | The properties and purification of a Blaberus craniifer plasma protein which enhances the activation of haemocyte prophenoloxidase by a β 1, 3-glucan | |
| EA201590611A1 (ru) | Новые молекулы, связывающие il-17a, и их медицинское применение | |
| PE20191033A1 (es) | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) | |
| PE20190352A1 (es) | Proteinas de fusion gdf 15 y usos de estas | |
| DOP2014000029A (es) | Proteínas y péptidos modificados. | |
| JOP20240283A1 (ar) | تركيبة منظف الشعر وفروة الرأس لإزالة السموم، طرق استخدامها واستخداماتها | |
| MX381183B (es) | Proteínas de fusión de serpina-fc de inmunoglobulina de humano y método de purificación de las mismas. | |
| MX2023009630A (es) | Composiciones en disolución acuosa para aumentar la estabilidad de las proteínas diméricas manipuladas genéticamente. | |
| MX2019000898A (es) | Amortiguador de lavado de cromatografia de afinidad. | |
| Barrett | Human cathepsin D | |
| MX2022011071A (es) | Composiciones que mejoran la estabilidad del poxvirus. | |
| Neves-Ferreira et al. | Isolation and characterization of DM40 and DM43, two snake venom metalloproteinase inhibitors from Didelphis marsupialis serum | |
| MX2023011629A (es) | Proteinas piv3 f prefusion estabilizadas. | |
| JOP20240281A1 (ar) | تركيبة منظف شعر ، طرق استخدامها واستخداماتها | |
| CL2022001035A1 (es) | Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas | |
| GEAP202516650A (en) | Stabilized pre-fusion hmpv fusion proteins | |
| US12331230B2 (en) | Protein-based adhesive and its modification | |
| BR112024001179A2 (pt) | Aminoácido supramolecular ou sal do mesmo, e método de preparação do mesmo e aplicação do mesmo | |
| EA201391546A1 (ru) | Противораковый слитый белок | |
| DE60227670D1 (de) | Aminosäuren-enthaltende zusammensetzungen, geeignet zur wundheilung, insbesondere zur behandlung des auges | |
| da Cunha Pereira et al. | Baltetin: a new C-type lectin-like isolated from Bothrops alternatus snake venom which act as a platelet aggregation inhibiting | |
| Heo et al. | Pueraria montana var. lobata root extract inhibits photoaging on skin through Nrf2 pathway. | |
| CL2023001889A1 (es) | Variantes de xilanasa | |
| CN108064229B (zh) | 蛋白质组合物的制造方法和蛋白质组合物 | |
| Vindas et al. | A novel pentameric phospholipase A2 myotoxin (PophPLA2) from the venom of the pit viper Porthidium ophryomegas |